cd19-cart
B-Cell Acute Lymphoblastic Leukemia
Explore 136 assets in B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
C36/100
Confidence
Indicative
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04184414CT.gov The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd19-cart (this asset) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early P1 | C · 36 |
| Etoposide | University of Washington | P3 | BBB |
| Crisantaspase | City of Hope Medical Center | P3 | BB |
| Vincristine Sulfate | City of Hope Medical Center | P3 | BB |
| Dasatinib | National Cancer Institute (NCI) | P3 | BB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BB |
| Nivestim | University of Washington | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Daunomycin | SWOG Cancer Research Network | P3 | BB |
+42 more in the B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for cd19-cart
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 53 |
| Mantle Cell Lymphoma | — | Early P1 | C · 34 |
| Follicular Lymphoma | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd19-cart in B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd19-cart-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →